Kestra Medical Technologies stock
KMTSNASDAQKestra Medical Technologies, Ltd., HealthcareISIN BMG524411052
45Score 45 out of 100, Weak
Price and trend
87 / 100
Price history
+6.8% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 19% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 50).
The price is 9.5% below its 52-week high. Largest decline in 2 years: 44% (April 2025 to August 2025).
Chart figures for advanced users
- SMA 50$27.31
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$24.06
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)50
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$17.87
- The lowest closing price of the last twelve months.
- Resistance$31.63
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Kestra Medical Technologies, Ltd. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $1.7B, is number 35 of 44 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $95.13M (up 59% year on year) and a loss of $131.61M.
- For fiscal 2027, analysts expect on average revenue of $140.88M (up 48.1%) and adjusted earnings per share of −$2.45.
Show more
- MEQIRI Score 45 out of 100 (Weak): rank 467 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $198.91M, financial debt $76.45M.Stability 52
Weaknesses
- Loss-makingLoss of $149.87M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$122.79M over the last 12 months.Fundamentals 17
- DilutionShare count up 18% since 2020.Capital allocation 25
Its standout strengths are technical analysis and momentum, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 44 to 45.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 31 Jul 2026, revenue rose 60.7% on the twelve months before. Revenue turned from negative at the start of the period to positive ($95.13M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 51%, operating −142%, net −138%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 10 Dec 2026in 28 days
- Last reported
- 14 Sep 2026EPS reported −$0.75 (expected −$0.62)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$2.45+0.1%
- Revenue
- $140.88M0.0%
- Earnings per share
- −$2.05+2.9%
- Revenue
- $196.04M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +10.2%Fiscal 2027 revenue guidance raised to 48% growth (prior guidance $137 million), with a long-term gross margin target in the mid-70% range versus 70% before.
“This compares to prior fiscal year 2027 revenue guidance of $137 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 14 Sep 2026 (fiscal Q1 2027), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 11 insiders sold, $13.53M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Moran Timothy P.Sale
3 Nov 2026, Chief Business Officer
- Shares
- 3,192
- Price
- $29.56
- Value
- $94,352
- Mahboob VaseemSale
29 Oct 2026, Chief Financial Officer
- Shares
- 4,788
- Price
- $30.60
- Value
- $146,503
- Mahboob VaseemSale
28 Oct 2026, Chief Financial Officer
- Shares
- 39,903
- Price
- $30.48
- Value
- $1.22M
Show 34 more
- Mahboob VaseemSale
27 Oct 2026, Chief Financial Officer
- Shares
- 34,809
- Price
- $30.04
- Value
- $1.05M
- Umberger Traci SSale
27 Oct 2026, See Remarks
- Shares
- 30,000
- Price
- $30.03
- Value
- $900,882
- Umberger Traci SSale
21 Oct 2026, See Remarks
- Shares
- 100,000
- Price
- $27.18
- Value
- $2.72M
- Webster Brian DanielSale
20 Oct 2026, See Remarks
- Shares
- 15,000
- Price
- $29.56
- Value
- $443,389
- Cohen Raymond WSale
30 Sept 2026, Board
- Shares
- 3,330
- Price
- $29.28
- Value
- $97,504
- Kwo ElizabethSale
21 Sept 2026, Board
- Shares
- 4,010
- Price
- $24.26
- Value
- $97,268
- Schwartz Jeffrey LawrenceSale
8 Sept 2026, Board
- Shares
- 3,890
- Price
- $25.18
- Value
- $97,942
- Hanley ConorSale
8 Sept 2026, Board
- Shares
- 5,694
- Price
- $25.25
- Value
- $143,779
- Reilly Kevin CSale
8 Sept 2026, Board
- Shares
- 2,932
- Price
- $25.13
- Value
- $73,677
- Ladone Mary KaySale
8 Sept 2026, Board
- Shares
- 3,908
- Price
- $25.20
- Value
- $98,464
- Webster Brian DanielSale
17 Aug 2026, See Remarks
- Shares
- 15,000
- Price
- $27.48
- Value
- $412,181
- Mahboob VaseemSale
7 Aug 2026, Chief Financial Officer
- Shares
- 26,287
- Price
- $25.88
- Value
- $680,383
- Ford Alfred J JrSale
4 Aug 2026, Chief Commercial Officer
- Shares
- 6,275
- Price
- $24.09
- Value
- $151,141
- Mahboob VaseemSale
4 Aug 2026, Chief Financial Officer
- Shares
- 6,995
- Price
- $24.68
- Value
- $172,635
- Umberger Traci SSale
4 Aug 2026, See Remarks
- Shares
- 3,580
- Price
- $24.04
- Value
- $86,073
- Webster Brian DanielSale
4 Aug 2026, See Remarks
- Shares
- 51,900
- Price
- $24.52
- Value
- $1.27M
- Moran Timothy P.Sale
3 Aug 2026, Chief Business Officer
- Shares
- 2,380
- Price
- $23.76
- Value
- $56,551
- Ford Alfred J JrSale
3 Aug 2026, Chief Commercial Officer
- Shares
- 13,015
- Price
- $23.90
- Value
- $311,118
- Mahboob VaseemSale
3 Aug 2026, Chief Financial Officer
- Shares
- 5,391
- Price
- $23.80
- Value
- $128,312
- Umberger Traci SSale
3 Aug 2026, See Remarks
- Shares
- 7,590
- Price
- $23.86
- Value
- $181,062
- Webster Brian DanielSale
3 Aug 2026, See Remarks
- Shares
- 13,017
- Price
- $23.92
- Value
- $311,424
- Moran Timothy P.Sale
31 Jul 2026, Chief Business Officer
- Shares
- 8,759
- Price
- $22.61
- Value
- $198,001
- Ford Alfred J JrSale
31 Jul 2026, Chief Commercial Officer
- Shares
- 8,681
- Price
- $22.61
- Value
- $196,284
- Mahboob VaseemSale
31 Jul 2026, Chief Financial Officer
- Shares
- 8,817
- Price
- $22.61
- Value
- $199,344
- Umberger Traci SSale
31 Jul 2026, See Remarks
- Shares
- 8,752
- Price
- $22.60
- Value
- $197,837
- Webster Brian DanielSale
31 Jul 2026, See Remarks
- Shares
- 8,948
- Price
- $22.60
- Value
- $202,260
- Moran Timothy P.Sale
30 Jul 2026, Chief Business Officer
- Shares
- 4,117
- Price
- $22.77
- Value
- $93,758
- Ford Alfred J JrSale
30 Jul 2026, Chief Commercial Officer
- Shares
- 5,936
- Price
- $22.76
- Value
- $135,121
- Mahboob VaseemSale
30 Jul 2026, Chief Financial Officer
- Shares
- 3,980
- Price
- $22.75
- Value
- $90,561
- Umberger Traci SSale
30 Jul 2026, See Remarks
- Shares
- 5,887
- Price
- $22.74
- Value
- $133,892
- Webster Brian DanielSale
30 Jul 2026, See Remarks
- Shares
- 7,857
- Price
- $22.72
- Value
- $178,531
- Webster Brian DanielSale
15 Jul 2026, See Remarks
- Shares
- 15,000
- Price
- $22.44
- Value
- $336,609
- Webster Brian DanielSale
15 Jun 2026, See Remarks
- Shares
- 15,000
- Price
- $20.81
- Value
- $312,143
- Webster Brian DanielSale
15 May 2026, See Remarks
- Shares
- 15,000
- Price
- $20.96
- Value
- $314,329
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Kestra Medical Technologies
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 45
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- AddLifeALIF-B.ST $2.17B59
- AzentaAZTA $2.14B52
- Bonesupport HoldingBONEX.ST $2.1B72
- DENTSPLY SIRONAXRAY $1.95B48
- SKAN GroupSKAN.SW $1.88B72
- LeMaitre VascularLMAT $1.81B70
- STAAR SurgicalSTAA $1.34B45
- GerresheimerGXI.DE $1.23B48
ETFs that hold Kestra Medical Technologies
Held by 8 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 0.80% | 0.68% | €5.31M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
Show 4 more
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.19B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €944.34M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Apr 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 6 Mar 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.